Personalized medicine: Progress and promise

Annual Review of Genomics and Human Genetics

Volumn 12, Issue , 2011, Pages 217-244

  Chan, Isaac S ^a,b,c   Ginsburg, Geoffrey S ^a,c  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical decision support; Comparative effectiveness research; Genomic medicine; Pharmacogenomics; Translational medicine

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CPG OLIGODEOXYNUCLEOTIDE; CYTOCHROME P450 2C9; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 28B; MESSENGER RNA; MICRORNA; ORGANIC ANION TRANSPORTER 2; PROTEIN MLH1; PROTEIN MSH2; PROTEOME; SMALL INTERFERING RNA; STAT1 PROTEIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX PROTEIN 1; WARFARIN;

ACUTE LEUKEMIA; ARTICLE; BACTERIAL VIRULENCE; BIPOLAR DISORDER; BREAST CANCER; CAENORHABDITIS ELEGANS; CANCER SURVIVAL; CHRONIC DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COLON CANCER; COMPARATIVE EFFECTIVENESS; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DNA METHYLATION; DRUG TARGETING; ENVIRONMENTAL FACTOR; EPIGENETICS; FAMILY HISTORY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC PRIVACY; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE HOMEOSTASIS; GRAFT REJECTION; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH EDUCATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; ISCHEMIC HEART DISEASE; LIFESTYLE; LUNG CANCER; LYMPHOMA; MAJOR DEPRESSION; MASS SPECTROMETRY; MEDICAL EDUCATION; MELANOMA; METABOLOMICS; MICROARRAY ANALYSIS; MICROBIAL GENETICS; MICROBIOME; MOLECULAR DIAGNOSIS; MULTIPLE SCLEROSIS; NEISSERIA MENINGITIDIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGAN TRANSPLANTATION; PATENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PREVENTIVE MEDICINE; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RICKETTSIA PROWAZEKII; RISK ASSESSMENT; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARD; STAPHYLOCOCCUS AUREUS; TRANSCRIPTOMICS; TREATMENT RESPONSE;

DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PREVENTIVE MEDICINE;

EID: 80052724921     PISSN: 15278204     EISSN: 1545293X     Source Type: Book Series    
DOI: 10.1146/annurev-genom-082410-101446     Document Type: Article

References (242)

1. Abbate A, Biondi-Zoccai GG, Brugaletta S, Liuzzo G, Biasucci LM. 2003. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin. Vasc. Med. 3:375-84
2. Abrahams E, Silver M. 2009. The case for personalized medicine. J. Diabetes Sci. Technol. 3:680-84
3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-11 (Pubitemid 30082188)
4. Am. Assoc. Cancer Res. Hum. Epigenome Task Force, Eur. Union Netw. Excell. Sci. Advis. Board. 2008. Moving AHEAD with an international human epigenome project. Nature 454:711-15
5. Apse KA, Biesecker BB, Giardiello FM, Fuller BP, Bernhardt BA. 2004. Perceptions of genetic discrimination among at-risk relatives of colorectal cancer patients. Genet. Med. 6:510-16 (Pubitemid 39576544)
6. Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, et al. 2002. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 21:7034-41 (Pubitemid 35252977)
7. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. 2009. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 58:2429-43
8. Baltimore D. 2001. Our genome unveiled. Nature 409:814-16 (Pubitemid 32165326)
9. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40:955-62
10. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-97
11. Bechah Y, El Karkouri K, Mediannikov O, Leroy Q, Pelletier N, et al. 2010. Genomic, proteomic, and transcriptomic analysis of virulent and avirulent Rickettsia prowazekii reveals its adaptive mutation capabilities. Genome Res. 20:655-63
12. Bennett JW, Glasziou PP. 2003. Computerised reminders and feedback in medication management: a systematic review of randomised controlled trials. Med. J. Aust. 178:217-22 (Pubitemid 36329215)
13. Bentley DR. 2006. Whole-genome re-sequencing. Curr. Opin. Genet. Dev. 16:545-52 (Pubitemid 44738530)
14. Bernstein BE, Meissner A, Lander ES. 2007. The mammalian epigenome. Cell 128:669-81 (Pubitemid 46273573)
15. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 98:13790-95 (Pubitemid 33115977)
16. Bird AP. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209-13 (Pubitemid 16016411)
17. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, et al. 2000. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-40 (Pubitemid 30625740)
18. Bolze A, Byun M, McDonald D, Morgan NV, Abhyankar A, et al. 2010. Whole-exome-sequencing-based discovery of human FADD deficiency. Am. J. Hum. Genet. 87:873-81
19. Bonetta L. 2010. Whole-genome sequencing breaks the cost barrier. Cell 141:917-19
20. Bray NJ. 2008. Gene expression in the etiology of schizophrenia. Schizophr. Bull. 34:412-18
21. Budhu A, Ji J,Wang XW. 2010. The clinical potential of microRNAs. J. Hematol. Oncol. 3:37
22. Burns DK. 2010. Developing pharmacogenetic evidence throughout clinical development. Clin. Pharmacol. Ther. 88:867-70
23. BuyseM, Loi S, van't Veer L, Viale G, DelorenziM, et al. 2006. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98:1183-92 (Pubitemid 44390989)
24. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6:857-66 (Pubitemid 44629897)
25. Cancer Genome Atlas Res. Netw. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-68
26. Chen B, Chen M, Paisley J, Zaas A, Woods C, et al. 2010. Bayesian inference of the number of factors in gene-expression analysis: application to human virus challenge studies. BMC Bioinforma. 11:552
27. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, et al. 2005. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res. 11:8623-31 (Pubitemid 43005909)
28. Cobleigh MA,VogelCL, Tripathy D, Robert NJ, Scholl S, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639-48 (Pubitemid 29415219)
29. Collins FS. 1999. Shattuck lecture: medical and societal consequences of the Human Genome Project. N. Engl. J. Med. 341:28-37 (Pubitemid 29293718)
30. Comabella M, Martin R. 2007. Genomics in multiple sclerosis: current state and future directions. J. Neuroimmunol. 187:1-8 (Pubitemid 47001533)
31. Core LJ,Waterfall JJ, Lis JT. 2008. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322:1845-48
32. Corwin EJ. 2004. The concept of epigenetics and its role in the development of cardiovascular disease: commentary on "New and emerging theories of cardiovascular disease." Biol. Res. Nurs. 6:11-16, 21-23 (Pubitemid 44005149)
33. Cronin M, PhoM,Dutta D, Stephans JC, Shak S, et al. 2004. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol. 164:35-42 (Pubitemid 38364587)
34. Dahl F, Stenberg J, Fredriksson S,Welch K, ZhangM, et al. 2007. Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc. Natl. Acad. Sci. USA 104:9387-92 (Pubitemid 47185789)
35. Davies J. 2001. In a map for human life, count the microbes, too. Science 291:2316 (Pubitemid 32231773)
36. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, et al. 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-70
37. Deloukas P, BentleyD. 2004. TheHapMap project and its application to genetic studies of drug response. Pharmacogenomics J. 4:88-90 (Pubitemid 38499991)
38. Deng M, Eisen H, Mehra M, Billingham M, Marboe C, et al. 2006. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6:150-60 (Pubitemid 43382213)
39. Devaskar SU, Thamotharan M. 2007. Metabolic programming in the pathogenesis of insulin resistance. Rev. Endocr. Metab. Disord. 8:105-13 (Pubitemid 47434650)
40. Dinan MA, Simmons LA, Snyderman R. 2010. Commentary: Personalized health planning and the Patient Protection and Affordable Care Act: an opportunity for academic medicine to lead health care reform. Acad. Med. 85:1665-68
41. Douglas PS, Ginsburg GS. 2008. Clinical genomic testing: getting it right. J. Cardiovasc. Transl. Res. 1:17-20
42. Driscoll C, Cashion A,HathawayD,ThompsonC,Conley Y, et al. 2006. Blood gene expression profiling in liver transplant recipients with hepatitis C virus and posttransplantation diabetes mellitus. Transplant. Proc. 38:3646-48 (Pubitemid 44908497)
43. Du X, Callister SJ, Manes NP, Adkins JN, Alexandridis RA, et al. 2008. A computational strategy to analyze label-free temporal bottom-up proteomics data. J. Proteome Res. 7:2595-604
44. Ebbels TM, Keun HC, Beckonert OP, BollardME, Lindon JC, et al. 2007. Prediction and classification of drug toxicity using probabilisticmodeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome Res. 6:4407-22 (Pubitemid 350158516)
45. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, et al. 2006. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38:1378-85 (Pubitemid 44837559)
46. Eisenstein EL, Lobach DF, Kawamoto K, Edwards R, Willis JM, et al. 2009. A randomized clinical trial of clinical decision support in a rural community health network serving lower income individuals: study design and baseline characteristics. Stud. Health Technol. Inform. 143:220-26
47. Evans R,WilliamsG, Baron H, Deng M, EisenH, et al. 2005. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am. J. Transplant. 5:1553-58 (Pubitemid 40839452)
48. Fed. Trade Comm. 2006. At-home genetic tests: A healthy dose of skepticism may be the best prescription. http://www.ftc.gov/bcp/edu/pubs/ consumer/health/hea02.shtm
49. FeeroWG, Guttmacher AE, Collins FS. 2010. Genomic medicine: an updated primer. N. Engl. J. Med. 362:2001-11
50. Feinberg AP,Vogelstein B. 1983. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 111:47-54 (Pubitemid 13125134)
51. Feng J, SunG,Yan J, NoltnerK,LiW, et al. 2009. Evidence forX-chromosomal schizophrenia associated with microRNA alterations. PLoS One 4:e6121
52. Fernandez Parguina A, Grigorian-Shamajian L, Agra RM,Teijeira-Fernandez E, Rosa I, et al. 2010. Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One 5:e13404
53. Fleischmann RD, AdamsMD, White O, Clayton RA, Kirkness EF, et al. 1995. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269:496-512
54. Francois P, Scherl A, Hochstrasser D, Schrenzel J. 2007. Proteomic approach to investigate MRSA. Methods Mol. Biol. 391:179-99 (Pubitemid 350190025)
55. Friede A. 2003. National Biospecimen Network Blueprint. Durham, NC: Constella
56. FruehFW,Gurwitz D. 2004. From pharmacogenetics to personalizedmedicine: a vital need for educating health professionals and the community. Pharmacogenomics 5:571-79 (Pubitemid 39023073)
57. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. 2002. The structure of haplotype blocks in the human genome. Science 296:2225-29 (Pubitemid 34680308)
58. Gail M, Greene M. 2000. Gail model and breast cancer. Lancet 355:1017
59. Garber AM, Tunis SR. 2009. Does comparative-effectiveness research threaten personalized medicine? N. Engl. J. Med. 360:1925-27
60. Garber K. 2005. Human Cancer Genome Project moving forward despite some doubts in community. J. Natl. Cancer Inst. 97:1322-24 (Pubitemid 41487794)
61. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401
62. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, et al. 2006. Metagenomic analysis of the human distal gut microbiome. Science 312:1355-59 (Pubitemid 43839542)
63. Ginsburg G,McCarthy J. 2001. Personalized medicine and the pharmaceutical industry. Trends Biotechnol. 19:491-96
64. Ginsburg GS. 2011. Application of molecular technologies to clinical medicine. In Cecil Medicine, ed. L Goldman, AI Schafer, pp. 199-203. Philadelphia: Elsevier. 24th ed.
65. GinsburgGS, Burke TW, Febbo P. 2008. Centralized biorepositories for genetic and genomic research. JAMA 299:1359-61 (Pubitemid 351439084)
66. Ginsburg GS, Willard HF. 2009. Genomic and personalized medicine: foundations and applications. Transl. Res. 154:277-87
67. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA 103:10834-39 (Pubitemid 44148381)
68. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, et al. 2006. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7:278
69. Goddard KA, Moore C, Ottman D, Szegda KL, Bradley L, Khoury MJ. 2007. Awareness and use of direct-to-consumer nutrigenomic tests, United States, 2006. Genet. Med. 9:510-17 (Pubitemid 47282039)
70. Goes FS, Sanders LL, Potash JB. 2008. The genetics of psychotic bipolar disorder. Curr. Psychiatry Rep. 10:178-89
71. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-37
72. Gonzalez-Angulo AM. 2010. Reply toD.H. Roukos andD.A.X. Schinagl et al. J. Clin. Oncol. 28:e282-83
73. Gonzalez-Angulo AM, Hennessy BT, Mills GB. 2010. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28:2777-83
74. Goodman J, Walsh V. 2001. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug. Cambridge: Camb. Univ. Press. 282 pp.
75. Gramling R,Nash J, Siren K, Eaton C, Culpepper L. 2004. Family physician self-efficacy with screening for inherited cancer risk. Ann. Fam. Med. 2:130-32 (Pubitemid 39329080)
76. Griffin JL, Shockcor JP. 2004. Metabolic profiles of cancer cells. Nat. Rev. Cancer 4:551-61 (Pubitemid 38868624)
77. Guffanti A, Iacono M, Pelucchi P, Kim N, Solda G, et al. 2009. A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC Genomics 10:163
78. Guttmacher AE, Collins FS. 2002. Genomic medicine: a primer. N. Engl. J. Med. 347:1512-20
79. Guttmacher AE, Collins FS, Carmona RH. 2004. The family history: more important than ever. N. Engl. J. Med. 351:2333-36 (Pubitemid 39552752)
80. Haga SB,Willard HF. 2006. Defining the spectrum of genome policy. Nat. Rev. Genet. 7:966-72 (Pubitemid 44871400)
81. Hall MA, McEwen JE, Barton JC, Walker AP, Howe EG, et al. 2005. Concerns in a primary care population about genetic discrimination by insurers. Genet. Med. 7:311-16 (Pubitemid 40827579)
82. Hannon GJ, Beach D. 1994. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257-61
83. HanssonMG, Dillner J, Bartram CR, Carlson JA, Helgesson G. 2006. Should donors be allowed to give broad consent to future biobank research? Lancet Oncol. 7:266-69 (Pubitemid 43286456)
84. Hariri S, Yoon PW, Moonesinghe R, Valdez R, Khoury MJ. 2006. Evaluation of family history as a risk factor and screening tool for detecting undiagnosed diabetes in a nationally representative survey population. Genet. Med. 8:752-59 (Pubitemid 44973763)
85. Hariri S, Yoon PW, Qureshi N, Valdez R, Scheuner MT, Khoury MJ. 2006. Family history of type 2 diabetes: a population-based screening tool for prevention? Genet. Med. 8:102-8
86. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, et al. 2011. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 470:264-68
87. He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW. 2008. The antisense transcriptomes of human cells. Science 322:1855-57
88. Hedley PL, Jorgensen P, Schlamowitz S,Wangari R, Moolman-Smook J, et al. 2009. The genetic basis of long QT and short QT syndromes: a mutation update. Hum. Mutat. 30:1486-511
89. Helgadottir A, Thorleifsson G,Manolescu A, Gretarsdottir S, Blondal T, et al. 2007. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316:1491-93 (Pubitemid 46906618)
90. Hemminki K, Sundquist J, Lorenzo Bermejo J. 2008. Familial risks for cancer as the basis for evidencebased clinical referral and counseling. Oncologist 13:239-47 (Pubitemid 351679899)
91. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, et al. 2002. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20:3815-25
92. HigashiMK, Veenstra DL, Kondo LM,Wittkowsky AK, Srinouanprachanh SL, et al. 2002. Association between CYP2C9 genetic variants and anticoagulation- related outcomes duringwarfarin therapy.JAMA 287:1690-98 (Pubitemid 34289221)
93. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TO. 2011. A catalog of published genome-wide association studies. http://www.genome.gov/gwastudies
94. Holleman A, Cheok MH, den Boer ML, YangW, Veerman AJ, et al. 2004. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J.Med. 351:533-42
95. Hornberger J, Chien R. 2010. Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice. Presented at Annu. San Antonio Breast Cancer Symp., 33rd, San Antonio, TX
96. HornseyM, Loman N, WarehamDW,Ellington MJ, PallenMJ, et al. 2011. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient,where resistance developed during tigecycline therapy. J. Antimicrob. Chemother. 66:1499-503
97. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. 2008. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359:1995-2004
98. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, et al. 2002. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-90 (Pubitemid 34525409)
99. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. 2008. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 181:8068-76
100. Hunter DJ, Khoury MJ, Drazen JM. 2008. Letting the genome out of the bottle: Will we get our wish? N. Engl. J. Med. 358:105-7
101. Inst. Med. Comm. Comp. Eff. Res. Prioritization. 2009. Initial National Priorities for Comparative Effectiveness Research.Washington, DC: National Academies. 227 pp.
102. Int. Soc. Biol. Environ. Repos. 2005. International Society for Biological and Environmental Repositories: 2004 Annual Meeting. Philadelphia: Taylor & Francis
103. Ioannidis JP, Allison DB, Ball CA, Coulibaly I, Cui X, et al. 2009. Repeatability of published microarray gene expression analyses. Nat. Genet. 41:149-55
104. Iorio MV, Croce CM. 2009. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27:5848-56
105. Issaq HJ, Veenstra TD. 2008. Would you prefer multiple reaction monitoring or antibodies with your biomarker validation? Expert Rev. Proteomics 5:761-63
106. Januchowski R, Prokop J, Jagodzinski PP. 2004. Role of epigenetic DNA alterations in the pathogenesis of systemic lupus erythematosus. J. Appl. Genet. 45:237-48 (Pubitemid 38834576)
107. Ji Q, Hao X,Meng Y, Zhang M, Desano J, et al. 2008. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8:266
108. Johnson AD, O'Donnell CJ. 2009. An open access database of genome-wide association results. BMC Med. Genet. 10:6
109. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-81 (Pubitemid 41266486)
110. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, et al. 2007. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12:934-45 (Pubitemid 47482696)
111. KannelW, Dawber T, Kagan A, Revotskie N, Stokes J III. 1961. Factors of risk in the development of coronary heart disease: six year follow-up experience: the Framingham Study. Ann. Intern.Med. 55:33-50
112. Kartha RV, Subramanian S. 2010. MicroRNAs in cardiovascular diseases: biology and potential clinical applications. J. Cardiovasc. Transl. Res. 3:256-70
113. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. 2005. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 330:765
114. Kawamoto K, Lobach DF,Willard HF, Ginsburg GS. 2009. A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med. Inform. Decis. Mak. 9:17
115. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, et al. 2010. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116:5161-67
116. Kennemann L, Didelot X, Aebischer T, Kuhn S, Drescher B, et al. 2011. Helicobacter pylori genome evolution during human infection. Proc. Natl. Acad. Sci. USA 108:5033-38
117. Keun HC. 2006. Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109:92-106 (Pubitemid 41740817)
118. King CR, Kraus MH, Aaronson SA. 1985. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-76 (Pubitemid 16248488)
119. Kittleson MM, Hare JM. 2005. Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy. Future Cardiol. 1:793-808
120. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308:385-89 (Pubitemid 40530070)
121. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360:753-64
122. Klitzman R. 2010. Views of discrimination among individuals confronting genetic disease. J. Genet. Couns. 19:68-83
123. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921 (Pubitemid 32165345)
124. Lapham EV, Kozma C, Weiss JO, Benkendorf JL, Wilson MA. 2000. The gap between practice and genetics education of health professionals: HuGEM survey results. Genet. Med. 2:226-31 (Pubitemid 32010829)
125. Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-54 (Pubitemid 24014542)
126. Lee SS, Mudaliar A. 2009. Racing forward: the Genomics and PersonalizedMedicine Act. Science 323:342
127. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, et al. 2010. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465:473-77
128. Levy S, SuttonG,Ng PC, Feuk L, Halpern AL, et al. 2007. The diploid genome sequence of an individual human. PLoS Biol. 5:e254
129. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115:787-98 (Pubitemid 38058492)
130. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. 2006. Microbial ecology: human gut microbes associated with obesity. Nature 444:1022-23 (Pubitemid 46018512)
131. Ley TJ, Mardis ER, Ding L, Fulton B,McLellan MD, et al. 2008. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:66-72
132. Link E, Parish S, Armitage J, Bowman L, Heath S, et al. 2008. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N. Engl. J. Med. 359:789-99
133. Liu J, Wyatt J, Altman D. 2006. Decision tools in health care: focus on the problem, not the solution. BMCMed. Inform. Decis. Mak. 6:4
134. LongWH, Xiao HS, Gu XM, Zhang QH, Yang HJ, et al. 2004. A universal microarray for detection of SARS coronavirus. J. Virol. Methods 121:57-63
135. Lu Q, Kaplan M, RayD, Zacharek S, Gutsch D, Richardson B. 2002. Demethylation of ITGAL(CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 46:1282-91 (Pubitemid 34525836)
136. Lugthart S, Cheok MH, den Boer ML, Yang W, Holleman A, et al. 2005. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7:375-86 (Pubitemid 40544654)
137. Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, et al. 2010. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N. Engl. J. Med. 362:1181-91
138. MaherCA, Kumar-Sinha C, Cao X,Kalyana-Sundaram S, Han B, et al. 2009. Transcriptome sequencing to detect gene fusions in cancer. Nature 458:97-101
139. Marshall E. 2009. Lawsuit challenges legal basis for patenting human genes. Science 324:1000-1
140. Marshall E. 2010. Cancer gene patents ruled invalid. Science 328:153
141. Martínez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, et al. 2007. Multiparameter immune profiling of operational tolerance in liver transplantation. Am. J. Transplant. 7:309-19 (Pubitemid 46096324)
142. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. 1984. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44:1002-7 (Pubitemid 14152782)
143. Mateos-Caceres PJ, Garcia-Mendez A, Lopez Farre A, Macaya C, Nunez A, et al. 2004. Proteomic analysis of plasma from patients during an acute coronary syndrome. J. Am. Coll. Cardiol. 44:1578-83 (Pubitemid 39369788)
144. Maughan KL, Lutterbie MA,Ham PS. 2010. Treatment of breast cancer. Am. Fam. Physician 81:1339-46
145. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. 2010. Genetic susceptibility to breast cancer. Mol. Oncol. 4:174-91
146. McCarthy JJ, Parker A, Salem R, Moliterno DJ, Wang Q, et al. 2004. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J. Med. Genet. 41:334-41 (Pubitemid 38608515)
147. McCarthy MI. 2010. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 363:2339-50
148. McGuire AL, Evans BJ, Caulfield T, BurkeW. 2010. Regulating direct-to-consumer personal genome testing. Science 330:181-82
149. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, et al. 2007. A common allele on chromosome 9 associated with coronary heart disease. Science 316:1488-91 (Pubitemid 46906617)
150. Mehta D,Menke A, Binder EB. 2010. Gene expression studies in major depression. Curr. Psychiatry Rep. 12:135-44
151. Metcalfe S, Hurworth R, Newstead J, Robins R. 2002. Needs assessment study of genetics education for general practitioners in Australia. Genet. Med. 4:71-77 (Pubitemid 44698581)
152. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de LencastreH, et al. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. USA 104:9451-56 (Pubitemid 47185800)
153. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, et al. 2010. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Investig. 120:1836-47
154. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, et al. 2009. A branched-chain amino acidrelated metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9:311-26
155. Nicholson JK, Connelly J, Lindon JC, Holmes E. 2002. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1:153-61 (Pubitemid 41646523)
156. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. 2005. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839-43 (Pubitemid 40839736)
157. Osheroff JA, Teich JM, Middleton B, Steen EB,Wright A, Detmer DE. 2007. A roadmap for national action on clinical decision support. J. Am. Med. Inform. Assoc. 14:141-45 (Pubitemid 46275496)
158. Paik S, Shak S,TangG,Kim C, Baker J, et al. 2004. Amultigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N. Engl. J. Med. 351:2817-26 (Pubitemid 40051905)
159. PalanisamyN, Ateeq B, Kalyana-Sundaram S, PfluegerD,RamnarayananK, et al. 2010. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16:793-98
160. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. 2008. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40:1413-15
161. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27:1160-67
162. Pasmant E, Laurendeau I, HeronD, VidaudM, VidaudD,Bieche I. 2007. Characterization of a germ-line deletion, including the entire INK4/ARFlocus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 67:3963-69 (Pubitemid 46762186)
163. Peltonen L, McKusick VA. 2001. Dissecting human disease in the postgenomic era. Science 291:1224-29 (Pubitemid 32173078)
164. Peterson DA, Frank DN, Pace NR, Gordon JI. 2008. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 3:417-27 (Pubitemid 351773097)
165. Peterson J, Garges S, Giovanni M, McInnes P, Wang L, et al. 2009. The NIH human microbiome project. Genome Res. 19:2317-23
166. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, et al. 2010. Gene-expression profiling for rejection surveillance after cardiac transplantation. N. Engl. J. Med. 362:1890-900
167. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, et al. 2010. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463:184-90
168. Polonikov AV, Ivanov VP, Solodilova MA. 2009. Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene-gene and gene-environment interactions for disease susceptibility. J. Hum. Genet. 54:440-49
169. Prendergast GC, Ziff EB. 1991. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 251:186-89 (Pubitemid 21916865)
170. PressMF, Pike MC, Chazin VR,HungG,Udove JA, et al. 1993. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53:4960-70 (Pubitemid 23326194)
171. Pushkarev D, Neff NF, Quake SR. 2009. Single-molecule sequencing of an individual human genome. Nat. Biotechnol. 27:847-50
172. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, et al. 2002. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:2240-50 (Pubitemid 34441651)
173. Rasko DA, Rosovitz MJ, Myers GS, Mongodin EF, Fricke WF, et al. 2008. The pangenome structure of Escherichia coli: comparative genomic analysis of E. coli commensal and pathogenic isolates. J. Bacteriol. 190:6881-93
174. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. 2006. Global variation in copy number in the human genome. Nature 444:444-54 (Pubitemid 44809057)
175. Rich E, BurkeW, Heaton C, Haga S, Pinsky L, et al. 2004. Reconsidering the family history in primary care. J. Gen. Intern. Med. 19:273-80 (Pubitemid 38388939)
176. Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, et al. 2010. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328:636-39
177. Rodriguez A, Vigorito E, Clare S,Warren MV, Couttet P, et al. 2007. Requirement of bic/microRNA-155 for normal immune function. Science 316:608-11 (Pubitemid 46683148)
178. Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, et al. 2010. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann. Intern. Med. 153:425-34
179. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:1937-47 (Pubitemid 34651353)
180. Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, et al. 2002. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation andDNAhypomethylation.Am. J. Pathol. 160:45-50 (Pubitemid 34052264)
181. Roukos DH. 2010. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J. Clin. Oncol. 28:e279-80
182. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, et al. 2005. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112:3868-75 (Pubitemid 43739484)
183. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, et al. 2007. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 357:443-53 (Pubitemid 47204873)
184. Savage DC. 1977. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 31:107-33
185. Scheuner MT, Sieverding P, Shekelle PG. 2008. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 299:1320-34 (Pubitemid 351439078)
186. Scheuner MT,Whitworth WC, McGruder H, Yoon PW, Khoury MJ. 2006. Expanding the definition of a positive family history for early-onset coronary heart disease. Genet. Med. 8:491-501
187. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-33 (Pubitemid 41510803)
188. Secr. Advis. Comm. Genet. Health Soc. 2008. U.S. system of oversight of genetic testing: a response to the charge of the secretary of health and human services. Rep., Dep. Health Hum. Serv., Washington, DC
189. Seib KL, Dougan G, Rappuoli R. 2009. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genet. 5:e1000612
190. Seibold MA, Schwartz DA. 2011. The lung: the natural boundary between nature and nurture. Annu. Rev. Physiol. 73:457-78
191. Sequist LV, BellDW, LynchTJ, Haber DA. 2007. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 25:587-95 (Pubitemid 350002967)
192. Service RF. 2006. The race for the $1000 genome. Science 311:1544-46
193. Shah SH, Hauser ER, Bain JR,MuehlbauerMJ, Haynes C, et al. 2009. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol. Syst. Biol. 5:258
194. Sharma S, Kelly TK, Jones PA. 2010. Epigenetics in cancer. Carcinogenesis 31:27-36
195. Shea S, DuMouchel W, Bahamonde L. 1996. A meta-analysis of 16 randomized controlled trials to evaluate computer-based clinical reminder systems for preventive care in the ambulatory setting. J. Am. Med. Inform. Assoc. 3:399-409 (Pubitemid 126445041)
196. Shimizu W. 2008. Clinical impact of genetic studies in lethal inherited cardiac arrhythmias. Circ. J. 72:1926-36
197. Simon R. 2003. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br. J. Cancer 89:1599-604 (Pubitemid 37464126)
198. Simpson A, John SL, Jury F, Niven R, Woodcock A, et al. 2006. Endotoxin exposure, CD14, and allergic disease: an interaction between genes and the environment. Am. J. Respir. Crit. CareMed. 174:386-92 (Pubitemid 44223118)
199. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, et al. 2007. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-85
200. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92 (Pubitemid 32222155)
201. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98:10869-74 (Pubitemid 32878711)
202. Sparano JA, Paik S. 2008. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26:721-28 (Pubitemid 351264384)
203. Starling R, Pham M, Valantine H, Miller L, Eisen H, et al. 2006. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J. Heart Lung Transplant. 25:1389-95 (Pubitemid 44909474)
204. Sugarbaker DJ, RichardsWG,Gordon GJ, Dong L, De Rienzo A, et al. 2008. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc. Natl. Acad. Sci. USA 105:3521-26 (Pubitemid 351723585)
205. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, et al. 2008. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321:956-60
206. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, et al. 2007. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 42:1137-41 (Pubitemid 46829201)
207. Tester DJ, Ackerman MJ. 2011. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation 123:1021-37
208. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al. 2005. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-37 (Pubitemid 41540110)
209. Thomas M, Lieberman J, Lal A. 2010. Desperately seeking microRNA targets. Nat. Struct. Mol. Biol. 17:1169-74
210. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139:120-29
211. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, et al. 2001. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 104:2641-44 (Pubitemid 33108126)
212. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. 2010. The role of BRCA mutation testing in determining breast cancer therapy. Nat. Rev. Clin. Oncol. 7:708-17
213. Tsurusaki Y, Osaka H, Hamanoue H, Shimbo H, Tsuji M, et al. 2011. Rapid detection of a mutation causing X-linked leucoencephalopathy by exome sequencing. J. Med. Genet. In press
214. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. 2007. The human microbiome project. Nature 449:804-10 (Pubitemid 47598620)
215. Umscheid CA. 2010. Maximizing the clinical utility of comparative effectiveness research. Clin. Pharmacol. Ther. 88:876-79
216. Van Baarsen LG, Bos CL, van der Pouw Kraan TC, Verweij CL. 2009. Transcription profiling of rheumatic diseases. Arthritis Res. Ther. 11:207
217. Van De Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009 (Pubitemid 35461656)
218. Van't Veer LJ,Dai H, van de Vijver MJ,He YD, Hart AA, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-36 (Pubitemid 34130608)
219. Vastag B. 2006. New clinical trials policy at FDA. Nat. Biotechnol. 24:1043
220. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
221. Vilar E, Gruber SB. 2010. Microsatellite instability in colorectal cancer: the stable evidence. Nat. Rev. Clin. Oncol. 7:153-62
222. Visel A, Zhu Y,May D, Afzal V, Gong E, et al. 2010. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 464:409-12
223. Voora D, McLeod H, Eby C, Gage B. 2005. The pharmacogenetics of coumarin therapy. Pharmacogenomics 6:503-13 (Pubitemid 41057388)
224. Walton R, Dovey S, Harvey E, Freemantle N. 1999. Computer support for determining drug dose: systematic review and meta-analysis. BMJ 318:984-90 (Pubitemid 29189091)
225. Wang J, Wang W, Li R, Li Y, Tian G, et al. 2008. The diploid genome sequence of an Asian individual. Nature 456:60-65
226. Wang K, Lee I, Carlson G, Hood L, Galas D. 2010. Systems biology and the discovery of diagnostic biomarkers. Dis. Markers 28:199-207
227. Weinshilboum R, Wang L. 2004. Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov. 3:739-48 (Pubitemid 39242826)
228. Weiss KM, Clark AG. 2002. Linkage disequilibrium and the mapping of complex human traits. Trends Genet. 18:19-24 (Pubitemid 34031854)
229. Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, et al. 2011. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305:1577-84
230. Westfall JM, Mold J, Fagnan L. 2007. Practice-based research: "Blue Highways" on the NIH roadmap. JAMA 297:403-6 (Pubitemid 46155803)
231. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, et al. 2008. The complete genome of an individual by massively parallel DNA sequencing. Nature 452:872-76 (Pubitemid 351550870)
232. Whellan DJ, Gaulden L, GattisWA, Granger B, Russell SD, et al. 2001. The benefit of implementing a heart failure disease management program. Arch. Intern. Med. 161:2223-28 (Pubitemid 32905003)
233. Wilkins-Haug L, Hill LD, Power ML, Holzman GB, Schulkin J. 2000. Gynecologists' training, knowledge, and experiences in genetics: a survey. Obstet. Gynecol. 95:421-24
234. Willard H, Angrist M, Ginsburg G. 2005. Genomic medicine: genetic variation and its impact on the future of health care. Philos. Trans. R. Soc. B 360:1543-50
235. Willard HF, Ginsburg GS. 2009. Genomic and Personalized Medicine. Amsterdam: Elsevier. 1478 pp.
236. Wingrove JA, Daniels SE, Sehnert AJ, TingleyW, Elashoff MR, et al. 2008. Correlation of peripheralblood gene expression with the extent of coronary artery stenosis. Circ. Cardiovasc. Genet. 1:31-38
237. Woodward C. 2009. Obama sparks an ideological donnybrook with his push to compare medical treatments. CMAJ 180:807
238. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, et al. 2011. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 13:255-62
239. Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. 2007. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J. Cell. Physiol. 212:285-92 (Pubitemid 47025616)
240. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, et al. 2010. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell 38:662-74
241. Zaas AK, ChenM, Varkey J, Veldman T, Hero AO III, et al. 2009. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6:207-17
242. Zhao Q, Caballero OL, Levy S, Stevenson BJ, Iseli C, et al. 2009. Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc. Natl. Acad. Sci. USA 106:1886-91